About Mohammad Hirmand
Mohammad Hirmand is a director at Whitehawk Therapeutics.
Form D filings name Mohammad Hirmand as an executive officer at Avenzo Therapeutics.
Mohammad Hirmand reports to the SEC as a director or officer of 3 public companies, including Turning Point Therapeutics (TPTX) and Medivation (MDVN).
Mohammad Hirmand first appears on SEC filings in 2015.
Experience
This experience comes from SEC filings. The years are when the filings name Mohammad Hirmand in the role, so the role may have started earlier or lasted longer.
WI
Whitehawk Therapeutics, Inc.
Director
2023 – 2026 · Public company (WHWK)
TI
Turning Point Therapeutics, Inc.
EVP and Chief Medical Officer
2019 – 2022 · Public company (TPTX)
MI
Medivation, Inc.
Interim Chief Medical Officer
2015 – 2016 · Public company (MDVN)
Key Colleagues at Startups
The people Mohammad Hirmand works with at each company, as listed on that company's latest Form D.
Avenzo Therapeutics, Inc. · Form D, Sep 5, 2025
CG
Carl Gordon
Director
GN
Garry Nicholson
Director
PM
Patrick Machado
Director
JL
Judith Li
Director
PT
Paolo Tombesi
Executive officer
SG
Simeon George
Director
SL
Scott Lipman
Executive officer
AC
Athena Countouriotis
Executive officer and director
BS
Brian Sun
Executive officer
JA
Jakob Dupont, M.D., M.A.
Director